Comparison of four models for end-stage liver disease in evaluating the prognosis of cirrhosis

Table 1 The clinical features of 166 patients with cirrhosis at 3 mo and 1 year follow-up¹

	3-mo follow-up		1-yr follow-up
Clinical features	Survival group	Death group	Survival group	Death group
Age (yr)	61.2 ± 12.7	66.1 ± 13.0a	60.3 ± 13.0	64.8 ± 12.4a
Bilirubin (μmol/L)	44.2 ± 40.1	106.2 ± 117.9a	43.1 ± 43.7	77.0 ± 91.0a
Creatinine (μmol/L)	85.5 ± 34.0	115.3 ± 67.7a	82.8 ± 32.2	103.8 ± 55.8a
INR	1.64 ± 0.51	2.21 ± 1.38a	1.58 ± 0.49	2.00 ± 1.07a
Serum sodium (mmol/L)	137.3 ± 4.9	130.4 ± 6.8b	137.7 ± 5.2	133.2 ± 6.3b
MELD	13.2 ± 5.6	20.5 ± 10.5b	8.63 ± 2.13	10.5 ± 2.52b
MELD-Na	14.7 ± 6.8	28.8 ± 15.0b	14.2 ± 5.31	20.5 ± 9.42b
iMELD	35.5 ± 7.6	49.0 ± 10.6b	34.1 ± 7.5	44.1 ± 10.3b
MESO	0.99 ± 0.42	1.59 ± 0.82b	0.93 ± 0.40	1.37 ± 0.70b

¹Data expressed as mean ± SD. MELD: Model for end-stage liver disease.

^aP < 0.05,

^bP < 0.01 vs the survival group.